Fig. 1From: Cost-effectiveness analysis (CEA) of IMRT plus C12 boost vs IMRT only in adenoid cystic carcinoma (ACC) of the head and neckNet monetary benefit (NMB) as a function of willingness to pay per LY (adjusted, 3.5% discounting)Back to article page